Sign In
Buy BCDA
$0.87
-0.0256 (-2.84%)
At Close: Jun 03, 2026
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
08:30am, Monday, 01'st Dec 2025
SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
08:15am, Monday, 24'th Nov 2025
SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript
12:11am, Thursday, 13'th Nov 2025
BioCardia, Inc. ( BCDA ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Miranda Peto Benvenuti Peter Altman - CEO, President & Director David McClung - Chief Financial Office
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
04:40pm, Wednesday, 12'th Nov 2025
SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
07:29pm, Wednesday, 05'th Nov 2025
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia Regains Compliance with Nasdaq Listing Requirements
08:00am, Thursday, 02'nd Oct 2025
SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, a
BioCardia Announces Pricing of Up To $12 Million Public Offering
09:15am, Thursday, 18'th Sep 2025
$6 million upfront with up to an additional $6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants $6 million upfront with up to an additional $6 million of
SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease
BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript
08:37pm, Monday, 11'th Aug 2025
BioCardia, Inc. (NASDAQ:BCDA ) Q2 2025 Earnings Conference Call August 11, 2025 7:00 AM ET Company Participants David McClung - Chief Financial Officer Miranda Peto Benvenuti - Corporate Participant P
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results
09:15am, Monday, 11'th Aug 2025
SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
03:18pm, Wednesday, 06'th Aug 2025
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
SUNNYVALE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary di
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
08:30am, Wednesday, 21'st May 2025
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript
07:40pm, Wednesday, 14'th May 2025
Start Time: 16:30 January 1, 0000 5:01 PM ET BioCardia, Inc. (NASDAQ:BCDA ) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Company Participants Peter Altman - President and CEO David McClu
